Intraocular Pressure

Between poor patient adherence and the inherent IOP peaks and troughs associated with eye drop-managed glaucoma, sustained-release medications are greatly needed, a presenter at the virtual OSN New York meeting said.

Patients with uncontrolled refractory glaucoma who underwent MicroPulse transscleral cyclophotocoagulation experienced a mean 28.6% IOP reduction from baseline at 2 years, according to a study.

Adding citicoline eye drops to IOP-lowering medications might reduce glaucoma progression in patients with worsening damage despite well-controlled IOP, according to a study.

When combined with cataract surgery, both Trabectome and a single Glaukos iStent reduce IOP and medication burden in glaucoma patients, but Trabectome may yield better results in the early postoperative period, according to a study.

The results of four randomized, double-masked, vehicle-controlled trials showed KPI-121 0.25% is safe and well tolerated with no unexpected treatment-related adverse events in patients with dry eye disease, according to a study.

Interim results from a phase 3b clinical trial in Europe showed Roclanda was non-inferior to Ganfort, according to a press release.

Aerpio Pharmaceuticals has completed enrollment in its phase 2 razuprotafib trial for patients with elevated IOP associated with open-angle glaucoma or ocular hypertension, according to a press release.

A low-cost nonvalved aqueous drainage implant significantly reduced IOP and glaucoma medication use in patients with refractory glaucoma, according to a retrospective review.

In this Healio Video Perspective, Dave Van Meter, CEO of Ivantis, discusses the global launch of the Hydrus microstent for the treatment of glaucoma, and the data accumulated with the device over more than 4 years.

In this Healio Video Perspective, Chris Calcaterra, chief operating officer at Glaukos Corp., discusses the company’s commitment to ophthalmologists and their patients throughout the coronavirus pandemic and going forward.